Investor Information

Amarillo Biosciences, Inc. (AMAR) is a specialty biopharmaceutical company dedicated to the development and commercialization of interferon alpha as a human therapeutic.  AMAR presently owns or licenses 4 US patents related to the low-dose oral delivery of interferon. AMAR also owns one issued US patent concerning Maxisal®, a dietary supplement for the relief of dry mouth.  The Company has completed over 100 studies in humans and animals.  AMAR’s low-dose oral technology reduces or eliminates side effects associated with high-dose injectable interferon.

The Company will focus on regulatory approval and global commercialization of low-dose oral interferon treatment of influenza, a potential multi-billion dollar market opportunity.  AMAR is also working toward FDA approval of oral interferon for prevention of relapse in patients with chronic active hepatitis C virus infection.

AMAR stock is publicly traded in the United States in the OTCBB market under the symbol: AMAR.OB.  In Germany, the Company stock is publicly traded on the Frankfurt, Stuttgart, Berlin-Bremen and Xetra exchanges as FZX WKN 917640.

For additional Information, please contact:

Bernard H. Cohen
Chief Financial Officer
Amarillo Biosciences, Inc.
4134 Business Park Drive
Amarillo, TX 79110
Phone: 806-376-1741
Copyright © 2018 Amarillo Biosciences. All Rights Reserved.
Built and hosted by Dark Roast Hosting